Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0DLHS | ISIN: US40637H1095 | Ticker-Symbol: RV7
Tradegate
10.05.24
17:16 Uhr
40,380 Euro
+0,320
+0,80 %
1-Jahres-Chart
HALOZYME THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
HALOZYME THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
39,58040,56010.05.
39,82040,31010.05.

Aktuelle News zur HALOZYME THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrBiotech Stocks To Watch: Halozyme Actionable Now After Earnings-Fueled Breakout1
MiHalozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript1
MiHalozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates4
MiEarnings call: Halozyme maintains positive outlook amid strong Q1 performance3
DiHALOZYME THERAPEUTICS, INC. - 8-K, Current Report3
DiHalozyme Therapeutics, Inc.: Halozyme Reports First Quarter 2024 Financial And Operating Results26Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Royalty Revenue Increased 21% YOY...
► Artikel lesen
DiExpert Ratings For Halozyme Therapeutics4
26.04.HALOZYME THERAPEUTICS, INC. - 8-K, Current Report2
16.04.9 Analysts Have This To Say About Halozyme Therapeutics9
29.02.TD Cowen bullish on Halozyme shares,says pipeline 'underappreciated'11
21.02.Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag8
21.02.Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views11
21.02.Earnings call: Halozyme reports robust Q4 and FY 2023 financial growth7
20.02.Halozyme Therapeutics Non-GAAP EPS of $0.82 misses by $0.01, revenue of $230.04M misses by $1.1M5
20.02.HALOZYME THERAPEUTICS, INC. - 10-K, Annual Report2
20.02.Halozyme Therapeutics: Q4 Earnings Insights2
20.02.HALOZYME THERAPEUTICS, INC. - 8-K, Current Report1
20.02.Halozyme Therapeutics, Inc.: Halozyme Reports Fourth Quarter And Full Year 2023 Financial And Operating Results169Reiterating 2024 Financial Guidance: Total Revenue of $915 -985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535 -585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted...
► Artikel lesen
19.02.Earnings Preview: Halozyme Therapeutics3
16.02.Halozyme Therapeutics Q4 2023 Earnings Preview1
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1